{"id":"NCT01245439","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis","officialTitle":"Local Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2014-08","completion":"2014-08","firstPosted":"2010-11-22","resultsPosted":"2015-11-03","lastUpdate":"2015-11-03"},"enrollment":65,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This open-label study will evaluate the safety, tolerability and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis (RA) on background non-biologic DMARDs who have an inadequate response to current non-biologic DMARDs. Patients will receive 8 mg/kg RoActemra/Actemra as an intravenous infusion every 24 weeks for a total of 6 infusions. The anticipated time on study treatment is 24 weeks.","primaryOutcome":{"measure":"Safety: Percentage of Participants With Treatment Emergent Adverse /Serious Adverse Events","timeFrame":"24 weeks","effectByArm":[{"arm":"Tocilizumab 8 mg/kg","deltaMin":90.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":17,"countries":["Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":65},"commonTop":["Elevated ALT 1.5- 3 ULN","Hypercholesterolaemia","Elevated ALT <45","Elevated AST <60","Hypertriglyceridaemia"]}}